The Institute of Bioengineering and Bioimaging (IBB) is located in Singapore's research and development hub for biomedical sciences, at the heart of Biopolis. The institute has office and laboratories located at Helios and Nanos Building and is staffed by 130 imaging experts, bioengineers, chemists, physicists, biologists and clinicians. IBB integrates the capabilities and technologies built up by the Institute of Bioengineering and Nanotechnology (IBN) and Singapore Bioimaging Consortium (SBIC), which were established in 2003 and 2004 respectively. The institute’s research activities are focused on biophotonics & bioimaging, bioengineering systems and biomedical devices & diagnostics. Equipped with state-of-the-art instruments, we spearhead multi-disciplinary, application-driven research at the interface of biology, chemistry, engineering and medicine, and work closely with stakeholders across the ecosystem to deliver innovative solutions in strategic areas such as cancer, infectious diseases, and food and nutrition.
IBB has made numerous scientific breakthrough and innovations, and published high-impact papers in leading scientific journals and accounts for a significant proportion of the Biomedical Research Council’s active patent portfolio. To date, IBB’s technologies have been translated and commercialised through more than 10 spin-off companies like Lucence, InvitroCue and Respiree.
To be a world-leading Bioengineering and Bioimaging Institute focused on the translation of technologies for the benefit of human and society.
The Institute of Bioengineering & Bioimaging strives to develop new technologies and engineering solutions addressing health, medical and sustainability challenges and to promote the advancement of disease prevention, diagnosis and therapy. With our comprehensive research capabilities at the interface of physical sciences, engineering and bioimaging, the institute brings together multi-disciplinary teams of leading scientists and engineers to tackle national and international health and technological priorities through partnership with both clinical and industry communities.